Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium
The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries
Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting
6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…Abstract Number: 2099 • 2019 ACR/ARP Annual Meeting
Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong
Background/Purpose: Screening for latent tuberculosis infection (LTBI) before the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) is recommended internationally especially in…Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting
Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…
- 1
- 2
- 3
- …
- 26
- Next Page »